Detailed financial statements for Perspective Therapeutics, Inc. (CATX): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Analysis Summary
Trailing-twelve-month margins: gross margin -419.4%, operating margin -342.2%, net margin -318.1%.
At the current price of $2.88, CATX has negative trailing earnings (P/E not meaningful) and an ROE of -41.56%. Market capitalisation stands at $328M.
Balance sheet quality for CATX: current ratio of 5.2, net cash position of $141.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $5.9M | $7.3M | $9.7M | $10.1M | $10.8M | $5.4M | $1.4M | $1.5M | 0 |
| Cost of Revenue | $3.9M | $4.1M | $4.3M | $4.6M | $4.9M | $6.2M | $3.0M | 0 | $2.3M | 0 |
| Gross Profit | $838000 | $1.8M | $3.0M | $5.1M | $5.1M | $4.6M | $2.4M | $1.4M | -$852000 | 0 |
| Research & Development | $965000 | $1.7M | $1.5M | $1.1M | $1.4M | $2.6M | $1.8M | $21.3M | $39.3M | $84.2M |
| Selling, General & Admin | $6.2M | $6.8M | $6.9M | $7.5M | $7.1M | $9.4M | $9.4M | $21.1M | $26.6M | $30.2M |
| Operating Expenses | $7.1M | $8.6M | $8.3M | $8.6M | $8.6M | $12.0M | $11.5M | $42.4M | $65.9M | $113.6M |
| Operating Income | -$6.3M | -$6.7M | -$5.3M | -$3.5M | -$3.4M | -$7.4M | -$9.1M | -$40.9M | -$66.8M | -$113.6M |
| EBITDA | -$6.2M | -$6.7M | -$5.1M | -$3.5M | -$3.4M | -$7.1M | -$8.5M | -$40.0M | -$64.5M | -$100.8M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $84000 | $48000 | $376000 |
| Pre-tax Income | -$6.2M | -$6.7M | -$5.1M | -$3.4M | -$3.4M | -$7.3M | -$8.5M | -$40.1M | -$80.4M | -$104.4M |
| Income Tax | -$145000 | -$29000 | -$294000 | -$177000 | -$199000 | 0 | 0 | -$2.7M | -$2.1M | -$793000 |
| Net Income | -$6.2M | -$6.7M | -$4.8M | -$3.3M | -$3.2M | -$7.3M | -$10.8M | -$46.5M | -$79.3M | -$103.1M |
| EPS | $-0.11 | $-0.12 | $-0.07 | $-0.05 | $-0.06 | $-0.50 | $-0.60 | $-0.85 | $-1.23 | $-1.40 |
| EPS (Diluted) | $-0.11 | $-0.12 | $-0.07 | $-0.05 | $-0.06 | $-0.50 | $-0.60 | $-0.85 | $-1.23 | $-1.40 |
| Shares Outstanding (Diluted) | $55.0M | $55.2M | $67.0M | $67.6M | $54.9M | $14.2M | $14.2M | $54.9M | $64.4M | $73.8M |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.9M | $2.6M | $5.3M | $2.4M | $9.6M | $55.9M | $21.0M | $9.2M | $61.6M | $30.6M |
| Short-term Investments | $3.0M | $825000 | 0 | 0 | 0 | 0 | $22.8M | 0 | $165.3M | $114.1M |
| Receivables | $726000 | $1.2M | $1.2M | $2.0M | $1.7M | $1.6M | $1.4M | $1.2M | $116000 | $1.0M |
| Inventory | $323000 | $516000 | $530000 | $645000 | $665000 | $1.4M | $1.4M | 0 | 0 | 0 |
| Total Current Assets | $10.3M | $5.5M | $7.3M | $5.5M | $12.3M | $59.3M | $53.2M | $16.8M | $231.2M | $148.4M |
| Property, Plant & Equipment | $1.1M | $1.3M | $1.6M | $2.7M | $2.7M | $2.5M | $371000 | $6.3M | $59.5M | $78.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24.1M | 0 | 0 |
| Intangible Assets | $230000 | $198000 | $162000 | $138000 | $130000 | $107000 | $25000 | $50.4M | $50.0M | $40.0M |
| Total Assets | $12.3M | $7.5M | $9.4M | $8.7M | $15.5M | $64.4M | $58.1M | $97.9M | $341.1M | $267.0M |
| Accounts Payable | $630000 | $1.4M | $683000 | $654000 | $494000 | $966000 | $1.5M | $6.9M | $10.3M | $20.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $49000 | $52000 | $56000 |
| Total Current Liabilities | $1.1M | $1.8M | $1.1M | $1.6M | $1.3M | $2.3M | $3.1M | $15.7M | $18.2M | $28.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.7M | $1.6M | $1.6M |
| Total Liabilities | $1.7M | $2.4M | $1.7M | $3.0M | $2.7M | $3.2M | $3.4M | $22.7M | $50.4M | $59.9M |
| Retained Earnings | -$72.6M | -$79.3M | -$84.5M | -$87.9M | -$89.5M | -$98.6M | -$105.9M | -$152.4M | -$231.7M | -$334.8M |
| Total Equity | $10.6M | $5.0M | $7.7M | $5.7M | $12.8M | $61.3M | $54.6M | $75.2M | $290.7M | $207.0M |
| Total Debt | 0 | 0 | 0 | $1.0M | $897000 | $524000 | $524000 | $2.6M | $4.1M | $3.3M |
| Net Debt | -$9.0M | -$3.4M | -$5.3M | -$1.4M | -$8.7M | -$55.4M | -$43.2M | -$6.7M | -$222.9M | -$141.5M |
| Working Capital | $9.2M | $3.6M | $6.2M | $3.9M | $11.0M | $57.1M | $50.1M | $1.2M | $212.9M | $119.7M |
Cash Flow (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$6.2M | -$6.7M | -$5.1M | -$3.4M | -$3.4M | -$7.3M | -$10.8M | -$46.5M | -$79.3M | -$103.1M |
| Depreciation & Amortization | $68000 | $80000 | $136000 | $147000 | $149000 | $248000 | $324000 | $986000 | $2.3M | $3.3M |
| Stock-based Compensation | $372000 | $607000 | $420000 | $495000 | $386000 | $1.1M | $807000 | $3.7M | $5.4M | $9.0M |
| Change in Working Capital | $17000 | $222000 | -$518000 | -$835000 | -$67000 | -$1.9M | -$1.7M | $2.9M | $31.8M | $1.7M |
| Operating Cash Flow | -$5.7M | -$5.7M | -$5.0M | -$3.6M | -$2.8M | -$7.7M | -$10.4M | -$36.9M | -$18.3M | -$82.5M |
| Capital Expenditure | -$549000 | -$337000 | -$444000 | -$273000 | -$381000 | -$266000 | -$282000 | -$1.1M | -$54.4M | -$12.7M |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.7M | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | -$11000 | -$11000 | -$11000 | -$11000 | -$9000 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$6.3M | -$6.0M | -$5.5M | -$3.9M | -$3.2M | -$8.0M | -$10.7M | -$38.0M | -$72.7M | -$95.2M |
Growth & Margins (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +24.4% | +23.5% | +32.3% | +3.9% | +7.4% | -49.8% | -73.5% | +1.4% | -100.0% | |
| Net Income Growth (YoY) | -8.7% | +27.6% | +32.6% | +2.5% | -128.1% | -48.0% | -332.2% | -70.5% | -30.1% | |
| EPS Growth (YoY) | -9.1% | +39.8% | +33.1% | -20.0% | -760.6% | -20.0% | -41.7% | -44.7% | -13.8% | |
| Shares Change (YoY) | +0.3% | +21.5% | +0.8% | -18.8% | -74.1% | +0.1% | +286.5% | +17.3% | +14.6% | |
| FCF Growth (YoY) | +3.4% | +9.2% | +28.7% | +17.8% | -147.9% | -33.9% | -255.6% | -91.4% | -31.0% | |
| Gross Margin | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | 42.8% | 43.7% | 100.0% | -58.6% | |
| Operating Margin | -132.5% | -113.6% | -72.2% | -35.9% | -34.2% | -68.5% | -168.1% | -2855.0% | -4594.0% | |
| EBITDA Margin | -130.0% | -113.1% | -70.3% | -35.9% | -34.1% | -66.2% | -156.6% | -2786.6% | -4435.4% | |
| Net Margin | -129.4% | -113.1% | -66.3% | -33.8% | -31.7% | -67.4% | -198.7% | -3243.2% | -5452.5% | |
| FCF Margin | -131.5% | -102.1% | -75.1% | -40.4% | -32.0% | -73.9% | -197.3% | -2648.9% | -5000.6% | |
| Effective Tax Rate | 2.4% | 0.4% | 5.7% | 5.1% | 5.9% | -0.0% | -0.0% | 6.6% | 2.6% | 0.8% |
Per-Share Data (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-0.11 | $-0.11 | $-0.08 | $-0.06 | $-0.06 | $-0.56 | $-0.75 | $-0.69 | $-1.13 | $-1.29 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $55.0M | $55.2M | $67.0M | $67.6M | $54.9M | $14.2M | $18.0M | $54.9M | $64.4M | $73.8M |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | -41.56% |
| Return on Invested Capital | -34.94% |
| Return on Assets | -29.70% |
| Gross Margin | -419.40% |
| Operating Margin | -34216.39% |
| Net Margin | -31812.57% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 6.61 |
Key Ratios (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -56.82 | -37.50 | -56.71 | -114.88 | -137.35 | -6.18 | -4.12 | -4.73 | -2.59 | -1.96 |
| P/B | 32.43 | 49.35 | 35.79 | 65.68 | 34.30 | 0.72 | 0.81 | 2.94 | 0.71 | 0.98 |
| P/S | 72.22 | 41.91 | 37.58 | 38.83 | 43.58 | 4.06 | 8.22 | 153.92 | 141.35 | 0.00 |
| Gross Margin | 17.6% | 31.1% | 41.7% | 52.9% | 50.9% | 42.8% | 43.7% | 100.0% | -58.6% | 0.0% |
| Operating Margin | -132.5% | -113.6% | -72.2% | -35.9% | -34.2% | -68.5% | -168.1% | -2855.0% | -4594.0% | 0.0% |
| Net Margin | -129.4% | -113.1% | -66.3% | -33.8% | -31.7% | -67.4% | -198.7% | -3243.2% | -5452.5% | 0.0% |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks